Published in J Mol Neurosci on July 10, 2017
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science (1993) 33.32
Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging (2002) 22.40
Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry (2008) 7.20
Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science (2012) 6.66
Parkinson's disease. Lancet (2009) 6.60
Participation in cognitively stimulating activities and risk of incident Alzheimer disease. JAMA (2002) 6.18
APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol (2010) 6.17
Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A (1993) 4.86
Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science (2001) 4.48
The ubiquitin pathway in Parkinson's disease. Nature (1998) 4.48
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol (2013) 4.16
The apolipoprotein E alleles as major susceptibility factors for Creutzfeldt-Jakob disease. The French Research Group on Epidemiology of Human Spongiform Encephalopathies. Lancet (1994) 4.15
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain (2010) 3.57
Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet (2009) 3.56
Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med (1995) 3.54
Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J Neurosci (2006) 3.37
Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci (2001) 3.10
Alzheimer's disease: the cholesterol connection. Nat Neurosci (2003) 2.99
Protection against Alzheimer's disease with apoE epsilon 2. Lancet (1994) 2.96
Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J Biol Chem (2008) 2.86
Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci U S A (2005) 2.45
Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A (2007) 2.43
A role for alpha-synuclein in the regulation of dopamine biosynthesis. J Neurosci (2002) 2.37
Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiol Dis (2011) 2.32
Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J Biol Chem (1998) 2.32
Lewy bodies. Proc Natl Acad Sci U S A (2006) 2.15
The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology (2004) 1.87
Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study. Neurology (2000) 1.85
Proteasomal inhibition by alpha-synuclein filaments and oligomers. J Biol Chem (2004) 1.84
Apolipoprotein J: structure and tissue distribution. Biochemistry (1990) 1.73
Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations. J Biol Chem (2000) 1.72
Membrane curvature induction and tubulation are common features of synucleins and apolipoproteins. J Biol Chem (2010) 1.69
Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line. J Biol Chem (2002) 1.64
Age at onset of Parkinson disease and apolipoprotein E genotypes. Am J Med Genet (2002) 1.56
APOE genotype and cognitive decline in a middle-aged cohort. Neurology (2005) 1.54
Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest (1994) 1.54
Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women. Am J Hum Genet (1996) 1.54
Alpha-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells. J Cell Sci (2005) 1.53
Association of APOE polymorphisms with disease severity in MS is limited to women. Neurology (2004) 1.51
The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J Neurosci (2000) 1.51
Apolipoprotein E epsilon4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia. Proc Natl Acad Sci U S A (2009) 1.49
α-Synuclein and dopamine at the crossroads of Parkinson's disease. Trends Neurosci (2010) 1.49
Apolipoprotein D. Biochim Biophys Acta (2000) 1.48
Age of onset in Huntington disease: sex specific influence of apolipoprotein E genotype and normal CAG repeat length. J Med Genet (1999) 1.45
Effect of apolipoprotein E genotype on hippocampal volume loss in aging healthy women. Neurology (2001) 1.43
APOE ε4 increases risk for dementia in pure synucleinopathies. JAMA Neurol (2013) 1.41
Impact of APOE in mild cognitive impairment. Neurology (2004) 1.37
APOE genotype is a major predictor of long-term progression of disability in MS. Neurology (2001) 1.35
Apolipoprotein E-containing lipoproteins protect neurons from apoptosis via a signaling pathway involving low-density lipoprotein receptor-related protein-1. J Neurosci (2007) 1.33
APOE-[epsilon]2 allele associated with higher prevalence of sporadic Parkinson disease. Neurology (2004) 1.30
A deadly spread: cellular mechanisms of α-synuclein transfer. Cell Death Differ (2011) 1.27
Alpha-synuclein, lipids and Parkinson's disease. Prog Lipid Res (2010) 1.24
A protective role for kidney apolipoprotein E. Regulation of mesangial cell proliferation and matrix expansion. J Biol Chem (2001) 1.23
Detection of ApoE E2, E3 and E4 alleles using MALDI-TOF mass spectrometry and the homogeneous mass-extend technology. Nucleic Acids Res (2005) 1.23
Extensive nuclear localization of alpha-synuclein in normal rat brain neurons revealed by a novel monoclonal antibody. Neuroscience (2007) 1.21
Wild-type but not Parkinson's disease-related ala-53 --> Thr mutant alpha -synuclein protects neuronal cells from apoptotic stimuli. J Biol Chem (2000) 1.18
Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. Hum Mol Genet (2000) 1.17
Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human alpha-synuclein. Neurobiol Dis (2005) 1.15
Plasma apolipoprotein A1 as a biomarker for Parkinson disease. Ann Neurol (2013) 1.14
Gender and age modify the association between APOE and AD-related neuropathology. Neurology (2001) 1.12
Serine 129 phosphorylation reduces the ability of alpha-synuclein to regulate tyrosine hydroxylase and protein phosphatase 2A in vitro and in vivo. J Biol Chem (2010) 1.11
{alpha}-synuclein and its A30P mutant affect actin cytoskeletal structure and dynamics. Mol Biol Cell (2009) 1.11
Apolipoprotein E4 domain interaction mediates detrimental effects on mitochondria and is a potential therapeutic target for Alzheimer disease. J Biol Chem (2010) 1.09
An evaluation of the impact of MAPT, SNCA and APOE on the burden of Alzheimer's and Lewy body pathology. J Neurol Neurosurg Psychiatry (2012) 1.09
alpha-Synuclein affects the MAPK pathway and accelerates cell death. J Biol Chem (2001) 1.08
Molecular characterization of human TRPM-2/clusterin, a gene associated with sperm maturation, apoptosis and neurodegeneration. Eur J Biochem (1994) 1.08
Genetic heterogeneity of apolipoprotein E and its influence on plasma lipid and lipoprotein levels. Hum Mutat (1994) 1.07
A large study reveals no association between APOE and Parkinson's disease. Neurobiol Dis (2012) 1.05
Lovastatin ameliorates alpha-synuclein accumulation and oxidation in transgenic mouse models of alpha-synucleinopathies. Exp Neurol (2009) 1.04
Estrogen receptor beta gene variants are associated with increased risk of Alzheimer's disease in women. Eur J Hum Genet (2005) 1.01
Are the estrogen receptors involved in Alzheimer's disease? Neurosci Lett (2001) 0.98
Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology. Eur J Neurosci (2010) 0.98
Apolipoprotein J (clusterin) induces cholesterol export from macrophage-foam cells: a potential anti-atherogenic function? Biochem J (1998) 0.98
Postural instability/gait disturbance in Parkinson's disease has distinct subtypes: an exploratory analysis. J Neurol Neurosurg Psychiatry (2010) 0.98
APOE genotype and survival in men and women with Alzheimer's disease. Neurology (2002) 0.97
Parkinson's disease-associated alpha-synuclein is a calmodulin substrate. J Biol Chem (2003) 0.96
Apo-Eε4 allele in conjunction with Aβ42 and tau in CSF: biomarker for Alzheimer's disease. Curr Alzheimer Res (2011) 0.95
The association between apolipoprotein E and traumatic brain injury severity and functional outcome in a rehabilitation sample. J Neurotrauma (2011) 0.94
HDL and cholesterol handling in the brain. Cardiovasc Res (2014) 0.94
Apolipoprotein E isoforms and lipoprotein metabolism. IUBMB Life (2014) 0.93
Dopamine and inhibitory action control: evidence from spontaneous eye blink rates. Exp Brain Res (2009) 0.93
Apolipoproteins in the brain: implications for neurological and psychiatric disorders. Clin Lipidol (2010) 0.93
The fusogenic tilted peptide (67-78) of α-synuclein is a cholesterol binding domain. Biochim Biophys Acta (2011) 0.92
Effect of age, ethnicity, and head injury on the association between APOE genotypes and Alzheimer's disease. Ann N Y Acad Sci (1996) 0.92
Apolipoprotein E epsilon4 allele in familial and sporadic Parkinson's disease. Neurosci Lett (2006) 0.91
Tetranectin and apolipoprotein A-I in cerebrospinal fluid as potential biomarkers for Parkinson's disease. Acta Neurol Scand (2010) 0.91
Prion-like propagation of human brain-derived alpha-synuclein in transgenic mice expressing human wild-type alpha-synuclein. Acta Neuropathol Commun (2015) 0.90
Parkinson's disease and apolipoprotein E: possible association with dementia but not age at onset. Genomics (2002) 0.90
Neuroprotective Sirtuin ratio reversed by ApoE4. Proc Natl Acad Sci U S A (2013) 0.89
Abnormal migration of human wild-type alpha-synuclein upon gel electrophoresis. Neurosci Lett (2004) 0.89
Brain lipid metabolism, apolipoprotein E and the pathophysiology of Alzheimer's disease. Neuropharmacology (2010) 0.89
Exercise, APOE genotype, and the evolution of the human lifespan. Trends Neurosci (2014) 0.89
Clusterin/apolipoprotein J is associated with cortical Lewy bodies: immunohistochemical study in cases with alpha-synucleinopathies. Acta Neuropathol (2002) 0.88
Apolipoprotein D expression in substantia nigra of Parkinson disease. Histol Histopathol (2006) 0.86
Alpha-synuclein overexpression increases dopamine toxicity in BE2-M17 cells. BMC Neurosci (2010) 0.85
Alpha synuclein aggregation: is it the toxic gain of function responsible for neurodegeneration in Parkinson's disease? Mech Ageing Dev (2001) 0.85
Heart rate variability and the risk of Parkinson disease: The Atherosclerosis Risk in Communities study. Ann Neurol (2015) 0.84
APOE epsilon4 is associated with impaired verbal learning in patients with MS. Neurology (2007) 0.84
Human plasma proapoA-I: isolation and amino-terminal sequence. Biochem Biophys Res Commun (1983) 0.84
Apolipoprotein E polymorphism in Japanese patients with Alzheimer's disease or vascular dementia. J Neurol Neurosurg Psychiatry (1994) 0.83
α-Synuclein Interacts with Lipoproteins in Plasma. J Mol Neurosci (2017) 0.75